Source: Health Products Regulatory Authority (ZA) Revision Year: 2022 Publisher: Cipla Medpro (Pty) Ltd., Building 9, Parc du Cap, Mispel Street, Bellville, 7530, RSA Customer care: 080 222 6662
Pharmacological classification: A 10.1 Antitussives and expectorants
ATC code: R05CB03
Carbocisteine reduces the viscosity of non-infected secretions from mucous cells in the respiratory tract.
Carbocisteine is used for its mucolytic activity in respiratory disorders associated with productive cough.
Carbocisteine is rapidly and well absorbed from the gastrointestinal tract and peak plasma concentrations occur about two (2) hours after an oral dose. It appears to penetrate into lung tissue and respiratory mucus. Carbocisteine is excreted in the urine as unchanged substance and metabolites. Acetylation, decarboxylation, and sulfoxidation have been identified as the major metabolic pathways. Sulfoxidation may be governed by genetic polymorphism.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
